<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216576</url>
  </required_header>
  <id_info>
    <org_study_id>19-458</org_study_id>
    <nct_id>NCT04216576</nct_id>
  </id_info>
  <brief_title>A Study of the Use of Text Message Reminders to Take Palbociclib</brief_title>
  <official_title>Oral Self-Management of Palbociclib (IbranceÂ®) Using Mobile Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether it is feasible (acceptable to participants)
      to use a smartphone app to send text message reminders to take palbociclib, and whether these
      reminders are effective at helping people remember to take palbociclib according to the
      treatment schedule.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2019</start_date>
  <completion_date type="Anticipated">December 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy rate of medication self-administration</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The effectiveness of a mobile technology intervention by calculating the proportion of the number of days that the participant accurately self-administers the medication divided by the number of days the medication should have been taken</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care + Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paper Drug Diary</intervention_name>
    <description>Participants will receive and use a paper Drug Diary and a paper medication calendar.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OhMD APP</intervention_name>
    <description>Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication</description>
    <arm_group_label>Standard of Care + Intervention</arm_group_label>
    <other_name>Unidirectional text messaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a breast cancer diagnosis who are initiating therapy on palbociclib
             (Ibrance)

          -  &gt;/= 18 years of age

          -  Able to speak, read and write English

          -  Willingness and ability to send and receive text messages with intervention app

          -  Own a mobile telephone &quot;smartphone&quot; with text messaging capabilities. Only iPhone or
             Android operating systems support OhMD Application

          -  Criteria applicable for both Control and Intervention groups

          -  Flip-phones do not support OhMD Application and thus ineligible to participate

          -  Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in
             conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)

        Exclusion Criteria:

          -  History of taking palbociclib (Ibrance)

          -  Patients whose caregivers coordinate their health care
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Barton-Burke, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Barton-Burke, PhD, RN</last_name>
    <phone>646-449-1074</phone>
    <email>bartonbm@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AnnMarie Mazzella, PhD, RN</last_name>
    <phone>646-449-1077</phone>
    <email>mazzella@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Barton-Burke, PhD, RN</last_name>
      <phone>646-449-1074</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Palbociclib</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>19-458</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

